Travere Therapeutics, Inc. - Common Stock (TVTX)

Historical Holders from Q4 2020 to Q3 2025

Symbol
TVTX on Nasdaq
CUSIP
89422G107
Type / Class
Equity / Common Stock
Shares outstanding
88.6M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
101M
Holdings value
$1.49B
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
208
Number of buys
115
Number of sells
-114
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Travere Therapeutics, Inc. - Common Stock (TVTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12.8% +47.8% $243M $80.8M 11.3M +49.9% JANUS HENDERSON GROUP PLC Jul 31, 2025
ARMISTICE CAPITAL, LLC 9.99% +3.7% $120M $20.4M 8.87M +20.6% Armistice Capital, LLC Mar 31, 2025
BlackRock, Inc. 7.5% -21.1% $90.2M -$17.9M 6.69M -16.6% BlackRock, Inc. Mar 31, 2025
VANGUARD GROUP INC 6.74% +18.2% $128M $21M 5.99M +19.6% The Vanguard Group Jun 30, 2025
MACQUARIE GROUP LTD 5.41% +10.2% $64.7M $7.25M 4.8M +12.6% Macquarie Group Limited Mar 31, 2025
Rock Springs Capital Management LP 3.3% -40.3% $39.4M -$27.7M 2.92M -41.3% Rock Springs Capital Management LP Mar 31, 2025
Woodline Partners LP 2.4% $28.5M 2.11M Woodline Partners LP Dec 31, 2024

Institutional Holders of Travere Therapeutics, Inc. - Common Stock (TVTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 93.6K $2.24M -$24.1M $23.90 2
2025 Q2 101M $1.49B +$13M $14.80 208
2025 Q1 98M $1.77B +$87.1M $17.92 214
2024 Q4 95.1M $1.66B +$205M $17.42 194
2024 Q3 82.7M $1.16B -$77.9M $13.99 177
2024 Q2 88M $736M +$16.2M $8.22 171
2024 Q1 87.6M $675M +$15.6M $7.71 171
2023 Q4 48.8K $439K -$1.69M $8.99 2
2023 Q3 82.4M $736M -$62.5M $8.94 165
2023 Q2 82.6M $1.27B -$87.6M $15.36 163
2023 Q1 84.2M $1.89B +$265M $22.49 171
2022 Q4 72.7M $1.53B +$30.9M $21.03 151
2022 Q3 65.9M $1.62B -$1.53M $24.64 161
2022 Q2 68.9M $1.67B +$17.1M $24.23 162
2022 Q1 68.3M $1.76B +$101M $25.77 163
2021 Q4 60.6M $1.88B +$62.2M $31.04 161
2021 Q3 60.8M $1.47B +$7.96M $24.25 144
2021 Q2 60.5M $883M -$73.5M $14.59 129
2021 Q1 62.6M $1.56B +$255M $24.97 147
2020 Q4 52.2M $1.42B +$1.41B $27.26 133